Proteostasis Therapeutics Inc  

(Public, NASDAQ:PTI)   Watch this stock  
Find more results for TSE:PTI
9.04
-0.02 (-0.22%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.80 - 9.15
52 week 5.27 - 13.99
Open 9.01
Vol / Avg. 6,212.00/30,120.00
Mkt cap 171.31M
P/E     -
Div/yield     -
EPS -1.22
Shares 19.14M
Beta     -
Inst. own 30%
Mar 30, 2016
Proteostasis Therapeutics Inc to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates
Mar 30, 2016
Proteostasis Therapeutics Inc to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -456.32% -580.71%
Operating margin -512.32% -568.97%
EBITD margin - -562.66%
Return on average assets -102.54% -164.35%
Return on average equity - -
Employees 42 -
CDP Score - -

Address

200 Technology Sq Fl 4
CAMBRIDGE, MA 02139-3578
United States - Map
+1-617-2250096 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Proteostasis Therapeutics, Inc. is a United States-based biopharmaceutical company developing small molecule therapeutics to treat diseases caused by defects in protein processing. The Company identifies selective drug candidates that modulate the proteostasis imbalance in the cell by combining the Disease-Relevant Translation, DRT platform, which is a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models. It is focused on developing a triple combination therapy for cystic fibrosis. It is focused on researching therapeutic strategies for modulating the unfolded protein response. It is focused on researching Usp14 inhibitors to manage the clearance of aggregation-prone proteins, such as tau in Alzheimer's disease and others. The Proteostasis Network consists of over 1,000 proteins organized into pathways. Its DRT platform combines genomics, proteomics and functional assays with medicinal chemistry and systems biology.

Officers and directors

Christopher K Mirabelli Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Meenu Chhabra President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Lance E. Thibault Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Po-Shun Lee M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Benito Munoz Senior Vice President - Drug Discovery
Bio & Compensation  - Reuters
Janet L. Smart Vice President - Intellectual Property & Legal Affaris
Bio & Compensation  - Reuters